Approach to Treating Heart Diseases

Researchers discover a new way to treat cardiovascular disease.

A certain protein found in blood vessel cells affects cardiovascular and cardiovascular diseases. Researchers discovered that the presence of many “thromoboxin A2 receptors” also prevents the growth of new blood vessels. The basic process was ultimately explained by a research team headed by Martin Luther University Hailey-Wittenburg (MLU). The research, published March 3 in arterosclerosis, thrombosis, and vascular biology, could lead to new treatments for cardiovascular disease.

Formation of blood vessels is a complex process. “Different obstacle and stimulating process should work together like a cog in a wheel. “Some blood vessel cells, therefore—the so-called endocel cells, play a key role in this process, regulating the exchange between blood and tissue,” explains lead author Prof. Ralph Bandorf, Institute of MLU. A pharmacist in a pharmacy.

Researchers investigated a protein that’s important for hemostasis: a thromoboxin A2 receptor that sticks platelets together and contributes to blood vessel constipation.
“We already knew that patients with cardiovascular disease and pathological changes in their blood vessels have increased amounts of these receptor proteins in their blood vessels.” Bandorf says. However, it was unclear whether there was any medical correlation to the discovery, in other words, whether there is a link between this growing number and the disease’s development.

Researchers have succeeded in closing the gap by understanding a complex interaction set by this receptor protein. Experiments show that the problem occurs when there is too much protein in the blood vessels.
“The occupant ensures that the preparation of the pro-inflammatory enzyme cycloxygen-2 is activated.” Explaining Bandorf, this enzyme in turn produces messenger substances that turn on the receptors. Implementing this constant and self-activating cycle of receptors in blood vessel cells means that cells have a harder time forming new blood vessels. It also significantly limits the function of endochelial cells.

Bandorf says, “Under the smile, you can see that the cells are really stressed if the receptors are high density.”
It is still unclear why protein is found more frequently in the blood vessel cells of people with cardiovascular disease.

“However, it’s a hopeful biomarker and could be an interesting target of pharmaceutical intervention,” Bandorf says. The harmful effects in cells can be reversed by substances that block the action of receptors or enzymes.
“Therefore receptor blockage could represent a new treatment option for patients with elevated blood vessels of thrombooxygen A2 receptors. Bandorf Says It Can Improve Urinary Verbs And Creation.

The first drug targeting protein is already going through clinical trials for use in other applications.

“While the substances have not been approved yet, the results of clinical trials indicate that they are well tolerated and can improve urinary function,” Bandorf says. Current research focused on the study of cell cultures and lab animals. More studies are needed on the potential benefits of treatment in preclinical disease models before they are tested or used in humans.

The work was financed by the Deutsche Fruschengsegemnschift (DFG, German Research Foundation) and the European Regional Development Fund (ERDF).

Reference: “A thromoboxin A2 receptor – hard cox – 2 – dependent feedback loop that affects endothelal homeostasis and anguish by Robert Accler, Ann Rapger, Michael Hawk, Mark Peterman, Sandra A. Hemkamer, Edward Schwedelum, Solomon Argan, Mike Fry, Oliver Weres, Andreas Cobral, Hike Brown and Ralph A. Bandorf, March 3, 2022, Arterioclerosis Thrombosis and Vascular Biology.

Leave a Comment